MedTrace Logo

PK of Piperacillin/Tazobactam in Adults Undergoing ECMO

NCT03467854 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 2

Last updated 2024-09-26

No results posted yet for this study

Summary

This study is designed to provide preliminary data to determine if concentrations of piperacillin/tazobactam change in patients with severe respiratory failure receiving extracorporeal membrane oxygenation (ECMO). The investigators hypothesize that patients will have significant changes in concentration measurements, specifically an increased clearance rate and increased volume of distribution, during ECMO as compared to critically ill patients.

Conditions

  • Acute Respiratory Failure With Hypoxia

Sponsors & Collaborators

Principal Investigators

  • Darryl Abrams, MD · Columbia University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-01
Primary Completion
2024-09-24
Completion
2024-09-24

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03467854 on ClinicalTrials.gov